Health Care·Pharmaceuticals·$153.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.42 | N/A | +31.24% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.42 | N/A | +31.24% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to ongoing projects. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering value through our ongoing projects.
Pfizer's strong EPS performance of $1.42, significantly above expectations, led to a positive stock reaction, with shares rising 4.15%. The company did not disclose revenue figures or future guidance, which leaves some uncertainty. Overall, the earnings report reflects Pfizer's solid performance in a competitive environment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SIMON PPTY GROUP INC REIT
Nov 1, 2021